AKBA(Akebia Therapeutics, Inc.) · 财务报表

AKBA(Akebia Therapeutics, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$211.65M$292.48M$194.62M$160.18M$236.20M
毛利润$60.98M$206.92M$120.47M$97.00M$196.73M
营业利润−$264.50M−$80.78M−$46.26M−$50.47M$23.50M
净利润−$282.02M−$94.23M−$51.92M−$69.41M−$5.34M
经营现金流−$252.97M−$73.15M−$23.38M−$40.66M$67.99M
自由现金流−$253.02M−$73.27M−$23.38M−$40.69M$67.70M
摊薄每股收益$-1.70$-0.52$-0.28$-0.33$-0.02

Akebia Therapeutics, Inc. AKBA